Literature DB >> 7131170

Fetal alcohol syndrome: a new primate model for binge drinking and its relevance to human ethanol teratogenesis.

S K Clarren, D M Bowden.   

Abstract

Ethanol was administered nasogastrically to four gravid pigtailed macaques (Macaca nemestrina) weekly from 40 days after conception to term. Three animals received 2.5 gm/kg and one received 4.1 gm/kg per dose. One animal aborted after the first dose of 2.5 gm/kg ethanol. Serum ethanol and acetaldehyde were measured after each dose in the other three animals, who carried to term. After delivery the infants were assessed for growth, dysmorphic features, and neurologic and psychological development over six months and were compared with 10 age- and sex-matched controls. Complete autopsies with neuropathologic examinations were performed. The animal exposed to the high dose had neurologic, developmental, and facial anomalies similar to those seen in human fetal alcohol syndrome. One of the animals exposed to the more moderate dosage was similarly but less severely affected. The study demonstrates that a model for binge drinking and fetal alcohol syndrome can be developed in a primate. The model should be useful in exploring the mechanisms of teratogenesis and in determining the median effective dose for the production of the various anomalies seen in fetal alcohol syndrome.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7131170     DOI: 10.1016/s0022-3476(82)80340-5

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  11 in total

1.  Alcohol and the fetus: a reasoned approach.

Authors:  R J Musto
Journal:  Can Fam Physician       Date:  1986-01       Impact factor: 3.275

Review 2.  The effects of prenatal alcohol exposure on behavior: rodent and primate studies.

Authors:  Mary L Schneider; Colleen F Moore; Miriam M Adkins
Journal:  Neuropsychol Rev       Date:  2011-04-19       Impact factor: 7.444

3.  Rapid induction of apoptosis in gastrulating mouse embryos by ethanol and its prevention by HB-EGF.

Authors:  Brian A Kilburn; Po Jen Chiang; Jun Wang; George R Flentke; Susan M Smith; D Randall Armant
Journal:  Alcohol Clin Exp Res       Date:  2006-01       Impact factor: 3.455

4.  Fetal alcohol syndrome and malignant disease.

Authors:  A Zaunschirm; W Muntean
Journal:  Eur J Pediatr       Date:  1984-02       Impact factor: 3.183

5.  Maternal alcohol exposure during mid-pregnancy dilates fetal cerebral arteries via endocannabinoid receptors.

Authors:  Olga Seleverstov; Ana Tobiasz; J Scott Jackson; Ryan Sullivan; Dejian Ma; J Pierce Sullivan; Steven Davison; Yada Akkhawattanangkul; Danielle L Tate; Terry Costello; Stacey Barnett; Wei Li; Giancarlo Mari; Alex M Dopico; Anna N Bukiya
Journal:  Alcohol       Date:  2017-05-18       Impact factor: 2.405

6.  Detecting Neurodevelopmental Effects of Early-Gestation Ethanol Exposure: A Nonhuman Primate Model of Ethanol Drinking During Pregnancy.

Authors:  Vanessa A Jimenez; Xiaojie Wang; Natali Newman; Nicole A R Walter; Steven Gonzales; Jamie O Lo; Mathew M Ford; Verginia C Cuzon Carlson; Kathleen A Grant; Christopher D Kroenke
Journal:  Alcohol Clin Exp Res       Date:  2019-01-11       Impact factor: 3.455

7.  Is there a fetal effect with low to moderate alcohol use before or during pregnancy?

Authors:  I Walpole; S Zubrick; J Pontré
Journal:  J Epidemiol Community Health       Date:  1990-12       Impact factor: 3.710

Review 8.  Ethanol and cognition: indirect effects, neurotoxicity and neuroprotection: a review.

Authors:  John C M Brust
Journal:  Int J Environ Res Public Health       Date:  2010-04-04       Impact factor: 3.390

9.  Ovarian stimulation by exogenous gonadotrophins in fetal ethanol-exposed immature rats.

Authors:  P K Rudeen; J Hagaman
Journal:  Experientia       Date:  1988-08-15

Review 10.  Fetal alcohol spectrum disorders: Zebrafish in the analysis of the milder and more prevalent form of the disease.

Authors:  Diane Seguin; Robert Gerlai
Journal:  Behav Brain Res       Date:  2017-10-05       Impact factor: 3.332

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.